ClinicalTrials.gg
CompletedNCT04905238Updated Nov 5, 2026

Obstructive Sleep Apnea and Biomarkers of Alzheimer's Disease

An interventional study of Continuous positive airway pressure in Sleep Apnea, Obstructive, sponsored by Alberto Alonso Fernandez. Completed at 2 sites in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Alberto Alonso Fernandez · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2020, registered May 2021).
Updated Nov 5, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 82 studies in Sleep Apnea, Obstructive with a site in Spain — 16 open to participants now, 19 under way, 6 of them phase 3. Sleep Apnea, Obstructive · Spain.

Enrollment
28th of 60
136 · median 128
Started
2020
with 4 others
No phase
46 of 82
6 open now
Registered
56th of 82
by date
Lead sponsor
2 of 82
Alberto Alonso Fernandez

Among the 82 studies in Sleep Apnea, Obstructive with a site in Spain, this one is the 28th largest by enrollment of the 60 interventional ones that give a count, is one of 5 that started in 2020, is one of 46 with no phase, and was the 56th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

16 of the 82 studies in Sleep Apnea, Obstructive with a site in Spain are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Sleep Apnea, Obstructive with a site in Spain, or all of them as a file.
02

Study summary

Clinical trial on the effect of continuous positive pressure (CPAP). Objectives: 1) To compare biomarkers of Alzheimer's disease in plasma samples from patients with Obstructive sleep apnea (OSA) and without OSA. 2) To determine if CPAP reduces biomarkers of Alzheimer's disease in plasma samples.

Read the detailed description

Randomized, parallel group, non-blinded, controlled clinical trial compared with conventional treatment.

A. Protocol and intervention Patients with an Apnea-Hypopnea index (AHI)>30 h-1 will be assigned, using a 1:1 randomization table, to lifestyle recommendations treatment or to lifestyle recommendations plus nasal CPAP, for a period of 4 months. CPAP pressure will be titled with automatic using an AutoSet II device, ResMed.

B. Sample size For the estimation of the sample size, previous data were used (PLoS ONE 2019;14(9): e0221255). In this case, in order to compare the effect of CPAP it would be necessary to randomize a total of 100 patients with OSA and 30 control subjects.

C. Ethical considerations

  • Indication of CPAP treatment for the prevention of Alzheimer's disease is not yet accepted.
  • Those patients with an urgent study indication for the diagnosis and treatment of respiratory sleep disorders (professional drivers, respiratory failure or risk professions) will be excluded from the project. In the other cases, the delay in healthcare for the performance of Polysomnography and CPAP titration exceeds the duration of the study, therefore that patients assigned to the control arm (conventional treatment) will not be exposed to a higher risk than the general population.

D. Methods.

. Polysomnography. It will be used as a screening test previous the randomization of the included patients. The exploration and its interpretation will be carried out following the recommendations of the American Academy of Sleep Medicine. Based on the results of this test, only those patients with an AHI will continue in the study when AHI >30 h-1. In these patients the determinations listed below will be carried out immediately before randomization (visit 1), at 4 weeks (visit 2), 16 weeks (visit 4) of allocation to the corresponding treatment group

  • Clinical data: The medication used and other associated diseases already diagnosed will be recorded.
  • Vital signs: recording of blood pressure, by means of a conventional triple taking, and heart rate.
  • Anthropometric characteristics: age and weight in basal conditions, the perimeter of the neck and waist / hip index will be measured. The lean mass index will be determined using a Bodystat 1500 impedance system (Bodystat Ltd, United Kingdom).
  • Questionnaires: Epworth Sleepiness Scale, generic health-related quality of life (SF-12 and EuroQoL) and daily physical activity (International Physical Activity Questionnaire or iPAQ).
  • Laboratory findings: blood count, coagulation, creatinine, serum sodium and potassium; glycated hemoglobin (HbA1c) and blood glucose and insulin levels in fasting, from these values will determine the resistance and sensitivity to insulin using the homeostatic model assessment (HOMA) and Quantitative insulin sensitivity check index (QUICKI) indices; total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides; and troponin I, homocysteine, N-terminal pro-brain natriuretic peptide (NT-pro BNP) and highly sensitive C-reactive protein.
  • Blood venous samples. 20 mL of venous blood will be collected, storing the plasma obtained at -80 ºC for subsequent determination of β amyloid biomarkers (Aβ40, Aβ42, tau y tau 181 (P-tau 181).
  • Night pulse oximetry. To assess the existence of residual nocturnal hypoxemia.
  • In the patients assigned to the CPAP treatment arm, a count of the hours of use of the CPAP will be carried out at each visit by directly reading the automatic counter of each equipment.

Statistic analysis The data will be expressed as mean ± standard deviation, median (interquartile range) or percentage, depending on their type and distribution. For comparison between groups Student's t-test, the U-Mann-Whitney or the chi-square test will be used, as appropriate. The relations between variables will be analyzed using Pearson's correlation and multiple linear regression analysis. The effect of treatment will be evaluated using general linear models and repeated measures analysis of variance, with multiple comparisons post-hoc using the Bonferroni test. A multiple logistic regression model will be applied to determine the related variables with a response to treatment. Values of p \<0.05 will be considered statistically significant. The statistical study will be performed with the SPSS program version 22.0.

03

Conditions studied

  • Sleep Apnea, Obstructive

Keywords

  • sleep apnea obstructive
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cases: patients with AHI > 30/h
  • Controls: subjects with AHI \< 5/h and Epworth \<10

Exclusion criteria

Exclusion Criteria:

  • Epworth>18
  • \<40Kg/M2
  • Arterial Hypertension
  • Diabetes Mellitus
  • Cerebrovascular disease
  • Ischemic heart disease
  • Cardiac arrhythmia
  • Chronic cardiovascular diseases
  • Daytime Oxygen saturation>95%
  • Risk professions (professional drivers)
  • Concomitant treatment with antihypertensives, statins, antidiabetics, beta- blockers or systemic .
  • Pretreatment with CPAP.
  • Participation in another clinical trial thirty days prior to randomization
  • Abnormal values of a cognitive test.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Active comparator
    Continuous positive airway pressure

    Diet and general life style recommendations plus continuous positive airway pressure (CPAP).

    Device: Continuous positive airway pressure

  • No intervention
    Conservative treatment

    Diet and general life style recommendations.

Interventions

  • DeviceContinuous positive airway pressure

    Continuous positive airway pressure

06

What researchers measure

Primary outcomes

  1. Change from baseline in β-amyloid 40 (Aβ-40 and/or Aβ42) concentration

    To compare the change in Aβ-40 and/or Aβ42 levels between the patients allocated to CPAP group and the control group

    Time frame: 4 months

  2. β-amyloid 40 (Aβ-40 and and/or Aβ42) concentration in OSA and in non-OSA patients

    To compare Aβ-40 and/or Aβ42 levels between OSA and non-OSA patients

    Time frame: Baseline

Secondary outcomes

  1. Phospho-Tau (P-Tau) concentration in OSA and in non-OSA patients

    To compare plasma concentrations of P-Tau in subjects with/without OSA.

    Time frame: Baseline

  2. Apolipoprotein E (APOE) concentration in OSA and in non-OSA patients

    To compare plasma concentrations of Apolipoprotein E (APOE) in subjects with/without OSA.

    Time frame: Baseline

  3. Neurofilament light chain (NfL) concentration in OSA and in non-OSA patients

    To compare plasma concentrations of NfL in subjects with/without OSA.

    Time frame: Baseline

  4. Microbiota population diversity from stool and nasopharyngeal samples in OSA and in non-OSA patients

    To compare microbiota population diversity from stool and nasopharyngeal samples in OSA and in non-OSA patients

    Time frame: Baseline

  5. Microbiota population abundance from stool and nasopharyngeal samples in OSA and in non-OSA patients

    To compare microbiota abundance from stool samples and nasopharyngeal samples in OSA and in non-OSA patients

    Time frame: Baseline

  6. Microbiota population color maps from stool and nasopharyngeal samples in OSA and in non-OSA patients

    To compare microbiota population color maps from stool and nasopharyngeal samples in OSA and in non-OSA patients

    Time frame: Baseline

  7. Associations of microbiota population diversity from stool and nasopharyngeal samples in OSA with biomarkers of Alzheimer's Disease

    To relate microbiota population diversity from stool and nasopharyngeal samples to biomarkers of Alzheimer's Disease

    Time frame: Baseline

  8. Associations of microbiota population abundance from stool and nasopharyngeal samples in OSA with biomarkers of Alzheimer's Disease

    To relate microbiota population abundance from stool and nasopharyngeal samples to biomarkers of Alzheimer's Disease

    Time frame: Baseline

  9. Associations of microbiota population color maps from stool and nasopharyngeal samples in OSA with biomarkers of Alzheimer's Disease

    To relate microbiota population color maps from stool and nasopharyngeal samples to biomarkers of Alzheimer's Disease

    Time frame: Baseline

  10. To evaluate the relationship of biomarkers of Alzheimer's disease and oropharyngeal and gut microbiota with the main classical markers of OSA and nocturnal hypoxic burden.

    To evaluate the relationship of biomarkers of Alzheimer's disease and oropharyngeal and gut microbiota with the main classical markers of OSA (AHI, AHI in REM, Di, arousals index, slow wave sleep time, SpO2 time\<90%, mean nocturnal SpO2, minimum SpO2, 3% and 4% desaturations index), as well as with nocturnal hypoxic burden related to respiratory events.

    Time frame: Baseline

  11. Associations between CPAP effects on oropharyngeal and gut microbiota, and biomarkers of Alzheimer's disease.

    To assess whether CPAP treatment modifies microbiota population diversity, abundance, and color maps from stool samples and nasopharyngeal samples of patients with OSA, and whether these changes correlate with variations in biomarkers of Alzheimer's disease

    Time frame: 4 months

  12. Change from baseline in biomarkers of Alzheimer's disease, and oropharyngeal and gut microbiota samples of patients with OSA according to the baseline hypoxic burden level and residual hypoxia.

    To assess whether residual hypoxia and baseline hypoxic burden results in a different response to CPAP/conservative treatment on biomarkers of Alzheimer's disease, and oropharyngeal and gut microbiota in patients with OSA.

    Time frame: 4 months

  13. To determine the relationship between compliance with CPAP treatment and the response on biomarkers of Alzheimer's disease and oropharyngeal and gut microbiota.

    To assess whether CPAP compliance (\>4 hours) results in a different response to biomarkers of Alzheimer's disease, and oropharyngeal and gut microbiota in patients with OSA.

    Time frame: 4 months

  14. Phosphorylated tau at threonine 217 (p-Tau217)

    To compare p-Tau217 levels in OSA and in non-OSA patients, and the change from baseline between the patients allocated to CPAP group and lifestyle recommendations treatment, and the lifestyle recommendations treatment alone.

    Time frame: Baseline and 4 months

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jul 2026, 71 months.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 71 months is above that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Apr 2025 → Jul 2026 and completion May 2025 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2021
First posted
May 27, 2021
StartActual
Jul 31, 2020
Primary completionActual
Jul 6, 2026was Apr 2025
CompletionActual
Jul 6, 2026was May 2025
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Nov 5, 2026
Primary completion
Apr 10, 2025→Jul 6, 2026
Nov 5, 2026
Study completion
May 6, 2025→Jul 6, 2026 (actual)
Nov 5, 2026
Enrollment
130 (estimated)→136 (actual)
Nov 5, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedPhosphorylated tau at threonine 217 (p-Tau217)Time frame: Baseline and 4 months
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Enrolling by invitation→Completed
    Primary completion Apr 10, 2025→Jul 6, 2026
    Study completion May 6, 2025→Jul 6, 2026 (now actual)
    Enrollment 130 (estimated)→136 (actual)
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedPhosphorylated tau at threonine 217 (p-Tau217)Time frame: Baseline and 4 months
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04905238
Lead sponsor
Alberto Alonso Fernandez
Collaborators
Instituto de Salud Carlos III
Responsible party
Alberto Alonso Fernandez (Principal investigator, Fundació d'investigació Sanitària de les Illes Balears) — Sponsor-investigator
First posted
May 27, 2021
Start date
Jul 31, 2020
Primary completion
Jul 6, 2026
Completion
Jul 6, 2026
Last update
Nov 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion